Duncan Bucknell (Hrsg.)World Protection and Exploitation
Pharmaceutical, Biotechnology and Chemical Inventions
World Protection and Exploitation
Ed. by Bucknell, Duncan. In collab. w. Bateman, John, Beaubien, Susan, and Anand, Pravin
Duncan Bucknell (Hrsg.)World Protection and Exploitation
Pharmaceutical, Biotechnology and Chemical Inventions
World Protection and Exploitation
Ed. by Bucknell, Duncan. In collab. w. Bateman, John, Beaubien, Susan, and Anand, Pravin
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book highlights the special issues arising in obtaining, commercialising, enforcing or attacking intellectual property rights in the pharmaceutical, biotechnology and chemical industries across the world's key jurisdictions.
Andere Kunden interessierten sich auch für
- The Chemical Weapons Convention269,99 €
- Issues of Arms Control Law and the Chemical Weapons Convention: Obligations Inter Se and Supervisory Mechanisms192,99 €
- Colm O'CinneideCurrent Legal Problems, Volume 62255,99 €
- William Fischer AgnewThe law and Practice Relating to Letters Patent for Inventions44,99 €
- T M GoodeveAbstract of Reported Cases Relating to Letters Patent for Inventions (bringing The Cases Down to The47,99 €
- Patents for Inventions38,99 €
- Brigitta Lurger / Wolfgang Faber (Hrsg.)Principles of European Law872,99 €
-
-
-
This book highlights the special issues arising in obtaining, commercialising, enforcing or attacking intellectual property rights in the pharmaceutical, biotechnology and chemical industries across the world's key jurisdictions.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- 1. Auflage
- Erscheinungstermin: 26. Mai 2011
- Englisch
- Abmessung: 256mm x 179mm x 119mm
- Gewicht: 3515g
- ISBN-13: 9780199289011
- ISBN-10: 0199289018
- Artikelnr.: 27861344
- Herstellerkennzeichnung
- Produktsicherheitsverantwortliche/r
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Oxford University Press
- 1. Auflage
- Erscheinungstermin: 26. Mai 2011
- Englisch
- Abmessung: 256mm x 179mm x 119mm
- Gewicht: 3515g
- ISBN-13: 9780199289011
- ISBN-10: 0199289018
- Artikelnr.: 27861344
- Herstellerkennzeichnung
- Produktsicherheitsverantwortliche/r
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Edited by Duncan Bucknell, Patent Attorney and IP Consultant, Australia
Part A. Introduction and Overview
Part B. Fundemental Concepts
1: Overview
2: International treaties
3: Skilled addressee
4: Interpretation of patent claims and specifications
5: Inventorship
6: Ownership
Part C. Obtaining patent rights
1: Overview
2: Drafting bioscience patents
3: Drafting pharmaceutical patents
4: Overview of procedure from filing to grant
5: Types of examination and when to use them
6: Prosecution strategies
7: Types of application and their use
8: Disclosure of information to the patent offices
Part D. The period of the monopoly
1: Overview
2: The patent term, renewal fees, withdrawals, cease and lapse
3: Extensions of term and supplementary protection certificates
Part E. Patent validity
1: Overview
2: Patent validity
3: Priority dates
4: Novelty
5: Grace period
6: Inventive step
7: Enablement/internal fair basis
8: Full description/stuffiness/written description
9: Utility
10: Indefiniteness
11: Secret use before prior date
12: Unity of invention
13: Fraud and misrepresentation
14: Lack of entitlement to the invention
Part F. Amendment
1: Overview
2: When Patents can be added?
3: What amendments are allowable?
4: Amended specifications
Part G. Invalidity proceedings and strategy
1: Overview
2: Third part intervention during prosecution
3: Opposition proceedings
4: Re-examination
5: Revocation/nullification proceedings
6: Declarations of validity
Part H. Infringement
1: Overview
2: Literal infringement
3: Infringement equivalents
4: Contributory infringement
5: Infringement proceedings and strategy
6: Remedies for patent infringements
7: Restrictions on remedies
Part I. Defences to infringement
1: Overview
2: Prior secret use
3: Experimental use and clinical trials
4: The bolar exemption
5: Contributory infringement
6: Parallel importing and exhaustion of rights
Part J. Patent litigation strategies
1: Overview
2: Court hierarchies
3: Overview of litigation
4: Preliminary injunctions
5: Split trials
6: Summary judgments
7: Multi-jurisdictional strategy
8: Practicalities of litigation
9: Settlement of litigation
Part K. Interaction between regulatory approval and patents
1: Overview
2: Regulatory bodies and relevant legislation
3: The pharmaceutical regulatory approval process
4: The biologicals regulatory approval process
5: The medical device regulatory approval process
6: The agricultural chemicals regulatory approval process
7: Regulatory filing strategies adopted by innovator companies
8: Regulatory filing strategies adopted by generic companies
9: Other relevant regulatory laws
Part L. Data exclusivity
1: Overview
2: Comparison of data exclusivity with other right
3: New chemical entity data exclusivity periods for pharmaceuticals
4: Other data exclusivity periods for pharmaceuticals
5: Certified (listed) patents and approval of generic drugs
6: Data exclusivity strategies adopted by innovator companies
7: Data exclusivity strategies adopted by generic companies
8: Medical devices, agricultural chemicals and other non-pharmaceuticals
Part M. Competition law
1: Overview
2: Legal basis for IP as an exception to competition (anti-trust) law
3: Technology transfer arrangements (including Block Exemption)
4: Tie-in clauses / Tie-out clauses
5: Licenses which extend beyond patent term
6: Disclosure to industry standard setting organizations
7: Unjustified threats of patent infringement proceedings
8: Competition issues in settlement of litigation
Part N. Other IP rights
1: Overview
2: Competition issues in settlement of litigation
3: Plant breeder's rights
4: Trade marks, passing off and unfair competition
Part O. Commercial arrangements
1: Oveview
2: Research and development collaboration
3: Commercialisation strategies
4: Licensing
5: Assignments
6: IP due diligence
7: Compulsory licenses
8: Compulsory use or acquisition by government
Tables and Figures
Part B. Fundemental Concepts
1: Overview
2: International treaties
3: Skilled addressee
4: Interpretation of patent claims and specifications
5: Inventorship
6: Ownership
Part C. Obtaining patent rights
1: Overview
2: Drafting bioscience patents
3: Drafting pharmaceutical patents
4: Overview of procedure from filing to grant
5: Types of examination and when to use them
6: Prosecution strategies
7: Types of application and their use
8: Disclosure of information to the patent offices
Part D. The period of the monopoly
1: Overview
2: The patent term, renewal fees, withdrawals, cease and lapse
3: Extensions of term and supplementary protection certificates
Part E. Patent validity
1: Overview
2: Patent validity
3: Priority dates
4: Novelty
5: Grace period
6: Inventive step
7: Enablement/internal fair basis
8: Full description/stuffiness/written description
9: Utility
10: Indefiniteness
11: Secret use before prior date
12: Unity of invention
13: Fraud and misrepresentation
14: Lack of entitlement to the invention
Part F. Amendment
1: Overview
2: When Patents can be added?
3: What amendments are allowable?
4: Amended specifications
Part G. Invalidity proceedings and strategy
1: Overview
2: Third part intervention during prosecution
3: Opposition proceedings
4: Re-examination
5: Revocation/nullification proceedings
6: Declarations of validity
Part H. Infringement
1: Overview
2: Literal infringement
3: Infringement equivalents
4: Contributory infringement
5: Infringement proceedings and strategy
6: Remedies for patent infringements
7: Restrictions on remedies
Part I. Defences to infringement
1: Overview
2: Prior secret use
3: Experimental use and clinical trials
4: The bolar exemption
5: Contributory infringement
6: Parallel importing and exhaustion of rights
Part J. Patent litigation strategies
1: Overview
2: Court hierarchies
3: Overview of litigation
4: Preliminary injunctions
5: Split trials
6: Summary judgments
7: Multi-jurisdictional strategy
8: Practicalities of litigation
9: Settlement of litigation
Part K. Interaction between regulatory approval and patents
1: Overview
2: Regulatory bodies and relevant legislation
3: The pharmaceutical regulatory approval process
4: The biologicals regulatory approval process
5: The medical device regulatory approval process
6: The agricultural chemicals regulatory approval process
7: Regulatory filing strategies adopted by innovator companies
8: Regulatory filing strategies adopted by generic companies
9: Other relevant regulatory laws
Part L. Data exclusivity
1: Overview
2: Comparison of data exclusivity with other right
3: New chemical entity data exclusivity periods for pharmaceuticals
4: Other data exclusivity periods for pharmaceuticals
5: Certified (listed) patents and approval of generic drugs
6: Data exclusivity strategies adopted by innovator companies
7: Data exclusivity strategies adopted by generic companies
8: Medical devices, agricultural chemicals and other non-pharmaceuticals
Part M. Competition law
1: Overview
2: Legal basis for IP as an exception to competition (anti-trust) law
3: Technology transfer arrangements (including Block Exemption)
4: Tie-in clauses / Tie-out clauses
5: Licenses which extend beyond patent term
6: Disclosure to industry standard setting organizations
7: Unjustified threats of patent infringement proceedings
8: Competition issues in settlement of litigation
Part N. Other IP rights
1: Overview
2: Competition issues in settlement of litigation
3: Plant breeder's rights
4: Trade marks, passing off and unfair competition
Part O. Commercial arrangements
1: Oveview
2: Research and development collaboration
3: Commercialisation strategies
4: Licensing
5: Assignments
6: IP due diligence
7: Compulsory licenses
8: Compulsory use or acquisition by government
Tables and Figures
Part A. Introduction and Overview
Part B. Fundemental Concepts
1: Overview
2: International treaties
3: Skilled addressee
4: Interpretation of patent claims and specifications
5: Inventorship
6: Ownership
Part C. Obtaining patent rights
1: Overview
2: Drafting bioscience patents
3: Drafting pharmaceutical patents
4: Overview of procedure from filing to grant
5: Types of examination and when to use them
6: Prosecution strategies
7: Types of application and their use
8: Disclosure of information to the patent offices
Part D. The period of the monopoly
1: Overview
2: The patent term, renewal fees, withdrawals, cease and lapse
3: Extensions of term and supplementary protection certificates
Part E. Patent validity
1: Overview
2: Patent validity
3: Priority dates
4: Novelty
5: Grace period
6: Inventive step
7: Enablement/internal fair basis
8: Full description/stuffiness/written description
9: Utility
10: Indefiniteness
11: Secret use before prior date
12: Unity of invention
13: Fraud and misrepresentation
14: Lack of entitlement to the invention
Part F. Amendment
1: Overview
2: When Patents can be added?
3: What amendments are allowable?
4: Amended specifications
Part G. Invalidity proceedings and strategy
1: Overview
2: Third part intervention during prosecution
3: Opposition proceedings
4: Re-examination
5: Revocation/nullification proceedings
6: Declarations of validity
Part H. Infringement
1: Overview
2: Literal infringement
3: Infringement equivalents
4: Contributory infringement
5: Infringement proceedings and strategy
6: Remedies for patent infringements
7: Restrictions on remedies
Part I. Defences to infringement
1: Overview
2: Prior secret use
3: Experimental use and clinical trials
4: The bolar exemption
5: Contributory infringement
6: Parallel importing and exhaustion of rights
Part J. Patent litigation strategies
1: Overview
2: Court hierarchies
3: Overview of litigation
4: Preliminary injunctions
5: Split trials
6: Summary judgments
7: Multi-jurisdictional strategy
8: Practicalities of litigation
9: Settlement of litigation
Part K. Interaction between regulatory approval and patents
1: Overview
2: Regulatory bodies and relevant legislation
3: The pharmaceutical regulatory approval process
4: The biologicals regulatory approval process
5: The medical device regulatory approval process
6: The agricultural chemicals regulatory approval process
7: Regulatory filing strategies adopted by innovator companies
8: Regulatory filing strategies adopted by generic companies
9: Other relevant regulatory laws
Part L. Data exclusivity
1: Overview
2: Comparison of data exclusivity with other right
3: New chemical entity data exclusivity periods for pharmaceuticals
4: Other data exclusivity periods for pharmaceuticals
5: Certified (listed) patents and approval of generic drugs
6: Data exclusivity strategies adopted by innovator companies
7: Data exclusivity strategies adopted by generic companies
8: Medical devices, agricultural chemicals and other non-pharmaceuticals
Part M. Competition law
1: Overview
2: Legal basis for IP as an exception to competition (anti-trust) law
3: Technology transfer arrangements (including Block Exemption)
4: Tie-in clauses / Tie-out clauses
5: Licenses which extend beyond patent term
6: Disclosure to industry standard setting organizations
7: Unjustified threats of patent infringement proceedings
8: Competition issues in settlement of litigation
Part N. Other IP rights
1: Overview
2: Competition issues in settlement of litigation
3: Plant breeder's rights
4: Trade marks, passing off and unfair competition
Part O. Commercial arrangements
1: Oveview
2: Research and development collaboration
3: Commercialisation strategies
4: Licensing
5: Assignments
6: IP due diligence
7: Compulsory licenses
8: Compulsory use or acquisition by government
Tables and Figures
Part B. Fundemental Concepts
1: Overview
2: International treaties
3: Skilled addressee
4: Interpretation of patent claims and specifications
5: Inventorship
6: Ownership
Part C. Obtaining patent rights
1: Overview
2: Drafting bioscience patents
3: Drafting pharmaceutical patents
4: Overview of procedure from filing to grant
5: Types of examination and when to use them
6: Prosecution strategies
7: Types of application and their use
8: Disclosure of information to the patent offices
Part D. The period of the monopoly
1: Overview
2: The patent term, renewal fees, withdrawals, cease and lapse
3: Extensions of term and supplementary protection certificates
Part E. Patent validity
1: Overview
2: Patent validity
3: Priority dates
4: Novelty
5: Grace period
6: Inventive step
7: Enablement/internal fair basis
8: Full description/stuffiness/written description
9: Utility
10: Indefiniteness
11: Secret use before prior date
12: Unity of invention
13: Fraud and misrepresentation
14: Lack of entitlement to the invention
Part F. Amendment
1: Overview
2: When Patents can be added?
3: What amendments are allowable?
4: Amended specifications
Part G. Invalidity proceedings and strategy
1: Overview
2: Third part intervention during prosecution
3: Opposition proceedings
4: Re-examination
5: Revocation/nullification proceedings
6: Declarations of validity
Part H. Infringement
1: Overview
2: Literal infringement
3: Infringement equivalents
4: Contributory infringement
5: Infringement proceedings and strategy
6: Remedies for patent infringements
7: Restrictions on remedies
Part I. Defences to infringement
1: Overview
2: Prior secret use
3: Experimental use and clinical trials
4: The bolar exemption
5: Contributory infringement
6: Parallel importing and exhaustion of rights
Part J. Patent litigation strategies
1: Overview
2: Court hierarchies
3: Overview of litigation
4: Preliminary injunctions
5: Split trials
6: Summary judgments
7: Multi-jurisdictional strategy
8: Practicalities of litigation
9: Settlement of litigation
Part K. Interaction between regulatory approval and patents
1: Overview
2: Regulatory bodies and relevant legislation
3: The pharmaceutical regulatory approval process
4: The biologicals regulatory approval process
5: The medical device regulatory approval process
6: The agricultural chemicals regulatory approval process
7: Regulatory filing strategies adopted by innovator companies
8: Regulatory filing strategies adopted by generic companies
9: Other relevant regulatory laws
Part L. Data exclusivity
1: Overview
2: Comparison of data exclusivity with other right
3: New chemical entity data exclusivity periods for pharmaceuticals
4: Other data exclusivity periods for pharmaceuticals
5: Certified (listed) patents and approval of generic drugs
6: Data exclusivity strategies adopted by innovator companies
7: Data exclusivity strategies adopted by generic companies
8: Medical devices, agricultural chemicals and other non-pharmaceuticals
Part M. Competition law
1: Overview
2: Legal basis for IP as an exception to competition (anti-trust) law
3: Technology transfer arrangements (including Block Exemption)
4: Tie-in clauses / Tie-out clauses
5: Licenses which extend beyond patent term
6: Disclosure to industry standard setting organizations
7: Unjustified threats of patent infringement proceedings
8: Competition issues in settlement of litigation
Part N. Other IP rights
1: Overview
2: Competition issues in settlement of litigation
3: Plant breeder's rights
4: Trade marks, passing off and unfair competition
Part O. Commercial arrangements
1: Oveview
2: Research and development collaboration
3: Commercialisation strategies
4: Licensing
5: Assignments
6: IP due diligence
7: Compulsory licenses
8: Compulsory use or acquisition by government
Tables and Figures